|
US3132171A
(en)
|
1962-06-18 |
1964-05-05 |
Strong Cobb Arner Inc |
3, 4-diphosphatophenyl-alanine and process for making same
|
|
US3998799A
(en)
|
1973-11-02 |
1976-12-21 |
Interx Research Corporation |
Novel, transient pro-drug forms of l-dopa
|
|
US3939253A
(en)
|
1973-11-02 |
1976-02-17 |
Interx Research Corporation |
Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
|
|
US3891696A
(en)
|
1973-11-02 |
1975-06-24 |
Interx Research Corp |
Novel, transient pro-drug forms of l-dopa
|
|
US4065566A
(en)
|
1975-04-17 |
1977-12-27 |
Interx Research Corporation |
N-Nicotinoyl-3,4-dinicotinoyloxy-L-phenylalanine and derivatives pharmaceutical compositions and methods containing same
|
|
US4035507A
(en)
|
1975-04-17 |
1977-07-12 |
Interx Research Corporation |
Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
|
|
US4163058A
(en)
|
1977-04-22 |
1979-07-31 |
Interx Research Corporation |
Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof
|
|
US4618484A
(en)
|
1983-03-30 |
1986-10-21 |
Yale University |
Composition and method for treatment of melanomas
|
|
US4508706A
(en)
|
1983-03-30 |
1985-04-02 |
Yale University |
Composition for increasing melanin in mammalian skin and hair
|
|
IT1213182B
(it)
|
1984-06-25 |
1989-12-14 |
Simes |
Derivati di composti a struttura catecolamminica.
|
|
IT1200427B
(it)
|
1985-03-22 |
1989-01-18 |
Afros Spa |
Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
|
|
JPH02138A
(ja)
|
1987-09-18 |
1990-01-05 |
Banyu Pharmaceut Co Ltd |
Ｌ‐ドーパ誘導体
|
|
IT1226727B
(it)
|
1988-07-29 |
1991-02-05 |
Simes |
Farmaci precursori della dopamina.
|
|
ES2070994T3
(es)
|
1989-04-20 |
1995-06-16 |
Zambon Spa |
Profarmaco de dopamina.
|
|
GB9102812D0
(en)
|
1991-02-11 |
1991-03-27 |
Enzymatix Ltd |
Compounds
|
|
IT1255471B
(it)
|
1992-07-30 |
1995-11-02 |
Zambon Spa |
Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
|
|
SE9203594D0
(sv)
|
1992-11-30 |
1992-11-30 |
Christer Nystroem |
Laekemedel i dispersa system
|
|
US5874468A
(en)
*
|
1996-12-26 |
1999-02-23 |
Yissum |
Brain targeted low molecular weight hydrophobic antioxidant compounds
|
|
US6576766B1
(en)
|
1997-11-12 |
2003-06-10 |
Ariad Pharmaceuticals, Inc. |
Signal transduction inhibitors, compositions containing them
|
|
US6365180B1
(en)
|
1998-01-20 |
2002-04-02 |
Glenn A. Meyer |
Oral liquid compositions
|
|
US6204257B1
(en)
|
1998-08-07 |
2001-03-20 |
Universtiy Of Kansas |
Water soluble prodrugs of hindered alcohols
|
|
CA2490626A1
(en)
|
2002-06-20 |
2003-12-31 |
Nippon Suisan Kaisha, Ltd. |
Prodrug, medicinal utilization thereof and process for producing the same
|
|
US7101912B2
(en)
|
2002-12-06 |
2006-09-05 |
Xenoport, Inc. |
Carbidopa prodrugs and derivatives, and compositions and uses thereof
|
|
WO2004069146A2
(en)
|
2003-02-07 |
2004-08-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
L-dopa amide derivatives and uses thereof
|
|
DE602004031134D1
(de)
|
2003-08-29 |
2011-03-03 |
Transform Pharmaceuticals Inc |
Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
|
|
ES2360759T3
(es)
|
2003-08-29 |
2011-06-08 |
Centocor Ortho Biotech Inc. |
Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
|
|
KR20060108692A
(ko)
|
2003-10-31 |
2006-10-18 |
알자 코포레이션 |
메트포르민의 개선된 흡수를 위한 조성물 및 제형
|
|
PT1751087E
(pt)
|
2004-06-04 |
2012-09-10 |
Xenoport Inc |
Derivados de levodopa e as suas composições e utilizações
|
|
CA2571726C
(en)
|
2004-07-06 |
2013-05-21 |
Abbott Laboratories |
Prodrugs of hiv protease inhibitors
|
|
SE0401842D0
(sv)
|
2004-07-12 |
2004-07-12 |
Dizlin Medical Design Ab |
Infusion and injection solution of levodopa
|
|
US7563821B2
(en)
|
2005-12-05 |
2009-07-21 |
Xenoport, Inc. |
Levodopa prodrug mesylate, compositions thereof, and uses thereof
|
|
WO2007138086A1
(en)
|
2006-05-31 |
2007-12-06 |
Solvay Pharmaceuticals Gmbh |
Long term 24 hour intestinal administration of levodopa/carbidopa
|
|
KR20090033871A
(ko)
|
2006-06-16 |
2009-04-06 |
솔베이 파마슈티칼스 비. 브이 |
비페프루녹스 및 ｌ-ｄｏｐａ를 포함하는 병용 제제
|
|
CA2673336A1
(en)
|
2006-12-21 |
2008-06-26 |
Xenoport, Inc. |
Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
|
|
GB0713189D0
(en)
|
2007-07-06 |
2007-08-15 |
Proximagen Ltd |
Amino acid derivatives
|
|
EP2252284B1
(en)
*
|
2008-02-06 |
2011-05-25 |
Wockhardt Research Centre |
Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
|
|
JP5757864B2
(ja)
|
2008-05-20 |
2015-08-05 |
ニューロジェシックス， インコーポレイテッド |
水溶性アセトアミノフェン類似体
|
|
US20130253056A1
(en)
|
2009-05-19 |
2013-09-26 |
Neuroderm, Ltd. |
Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
|
|
PL2432454T3
(pl)
|
2009-05-19 |
2017-10-31 |
Neuroderm Ltd |
Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy
|
|
SG179135A1
(en)
|
2009-09-14 |
2012-05-30 |
Abbott Lab |
Methods for treating psoriasis
|
|
WO2011056240A2
(en)
|
2009-11-09 |
2011-05-12 |
Xenoport, Inc. |
Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
|
|
EA026419B1
(ru)
|
2010-03-04 |
2017-04-28 |
Орион Корпорейшн |
Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
|
|
WO2011109767A2
(en)
|
2010-03-04 |
2011-09-09 |
University Of Notre Dame Du Lac |
Gelatinase inhibitors and prodrugs
|
|
EP2575884B1
(en)
|
2010-06-03 |
2018-07-18 |
AbbVie Biotechnology Ltd |
Uses and compositions for treatment of hidradenitis suppurativa (hs)
|
|
PT2640358T
(pt)
|
2010-11-15 |
2018-02-23 |
Neuroderm Ltd |
Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos
|
|
CN103228618B
(zh)
|
2010-12-02 |
2016-02-17 |
小野药品工业株式会社 |
新化合物及其医药用途
|
|
WO2012079072A2
(en)
|
2010-12-10 |
2012-06-14 |
Synagile Corporation |
Subcutaneously infusible levodopa prodrug compositions and methods of infusion
|
|
US8765189B2
(en)
|
2011-05-13 |
2014-07-01 |
Howmedica Osteonic Corp. |
Organophosphorous and multivalent metal compound compositions and methods
|
|
AU2014229127B2
(en)
|
2013-03-13 |
2018-04-05 |
Neuroderm Ltd |
Method for treatment of parkinson's disease
|
|
CN112521305B
(zh)
|
2013-03-15 |
2023-04-25 |
苏州泰飞尔医药有限公司 |
治疗帕金森疾病的新型高穿透力药物及其药物组合物
|
|
US10258585B2
(en)
|
2014-03-13 |
2019-04-16 |
Neuroderm, Ltd. |
DOPA decarboxylase inhibitor compositions
|
|
DK3116475T3
(da)
|
2014-03-13 |
2020-12-07 |
Neuroderm Ltd |
Dopa-decarboxylasehæmmersammensætninger
|
|
RU2021103000A
(ru)
|
2014-10-21 |
2021-03-01 |
Эббви Инк. |
Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
|
|
MA41377A
(fr)
|
2015-01-20 |
2017-11-28 |
Abbvie Inc |
Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
|
|
US20240024338A1
(en)
|
2016-04-20 |
2024-01-25 |
Abbvie Inc. |
Carbidopa and l-dopa prodrugs and methods of use
|
|
EP4295909A3
(en)
|
2016-04-20 |
2024-07-17 |
AbbVie Inc. |
Carbidopa and l-dopa prodrugs and methods of use
|
|
BR112019001229B1
(pt)
|
2016-07-22 |
2022-11-16 |
Syngenta Participations Ag |
Composto derivado de oxadiazol, composição agroquímica compreendendo o mesmo, método para controlar ou impedir infestação de plantas úteis por microrganismos fitopatogênicos e uso do referido composto como fungicida
|
|
US20190224153A1
(en)
|
2016-09-29 |
2019-07-25 |
Berlirem Gmbh |
L-dopa derivatives for the treatment of neurological diseases
|
|
WO2018154447A1
(en)
|
2017-02-21 |
2018-08-30 |
Neuroderm Ltd |
Dopa decarboxylase inhibitor compositions
|
|
BR112021009353A2
(pt)
|
2018-11-15 |
2021-11-23 |
Abbvie Inc |
Formulações farmacêuticas para administração subcutânea
|
|
US11213502B1
(en)
|
2020-11-17 |
2022-01-04 |
Neuroderm, Ltd. |
Method for treatment of parkinson's disease
|
|
US11331293B1
(en)
|
2020-11-17 |
2022-05-17 |
Neuroderm, Ltd. |
Method for treatment of Parkinson's disease
|
|
WO2023049534A2
(en)
|
2021-10-27 |
2023-03-30 |
Abbvie Inc. |
Subcutaneously administered treatments for advanced parkinson's disease
|